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Characterization of the DNA Copy-Number Genome
in the Blood of Cutaneous T-Cell Lymphoma Patients
William M. Lin1, Julia M. Lewis1, Renata B. Filler1, Badri G. Modi1, Kacie R. Carlson1, Swapna Reddy1,
Adam Thornberg2, Gordon Saksena3, Sheila Umlauf 2, Patrick A. Oberholzer3,4, Maria Karpova5,
Gad Getz3, Shrikant Mane2, Levi A. Garraway3,4, Reinhard Dummer5, Carole L. Berger1,
Richard L. Edelson1 and Michael Girardi1
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous non-Hodgkin’s lymphoma that may variably involve the
skin, lymph nodes, and peripheral blood. Malignant burden ranges from cutaneous patches and plaques with
little evidence of blood involvement to erythroderma often in association with frank leukemia, as in Se´zary
syndrome. Toward a better understanding of the pathogenesis of this CD4þ T-cell malignancy, we conducted a
high-resolution genomic analysis combining DNA (23 samples) and mRNA (12 samples) data of peripheral blood
isolates from CTCL patients across a spectrum of stages. Strikingly, even patients with limited involvement, e.g.,
normal CD4 counts, contained significant copy-number alterations. Defining genomic characteristics of CTCL
blood involvement included gains on 8q and 17q, and deletions on 17p and chromosome 10. A consensus
analysis of 108 leukemic CTCL samples demonstrated global similarities among patients with varied blood
involvement, narrowing 38 of 62 loci. Toward an annotated framework for in vitro testing, we also characterized
genomic alterations in five CTCL cell lines (HH, HUT78, PNO, SeAx, and Sez4), revealing intact core features of
leukemic CTCL. Together, these studies produce the most comprehensive view of the leukemic CTCL genome
to date, with implications for pathogenesis, molecular classification, and potential future therapeutic
developments.
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INTRODUCTION
Cutaneous T-cell lymphoma (CTCL) is a clinically hetero-
geneous malignancy of CD4þ skin-homing T cells (Berger
and Edelson, 2003; Willemze and Meijer, 2006). Early stages
of CTCL principally involve the skin; however, the risk of
peripheral blood involvement increases with advancing stage
(Schechter et al., 1987). Even patients with limited disease
(stage IA, o10% body surface area involvement) may show
evidence of an expanding clone in the blood as evidenced by
flow cytometric T-cell subset analyses. Clonal expansion of
malignant cells within the peripheral blood is also associated
with a loss of the residual T-cell receptor diversity (Yawalkar
et al., 2003), increased T-regulatory activity (Berger et al.,
2005), and diminished CD8 counts (Klemke et al., 2005;
Vonderheid et al., 2006). Responses to immune modifying
treatments such as photopheresis (Girardi et al., 2003) and
IFN-a (Olsen, 2003) have strongly suggested the immuno-
genicity of CTCL; yet, our understanding of the pathogenesis
of this malignancy is still limited. Moreover, stage III
and IV CTCL, particularly in those with depressed CD8
compartments, is commonly lethal, with survival not
improved by conventional systemic therapies (Girardi et al.,
2003; Olsen, 2003; Klemke et al., 2005; Vonderheid et al.,
2006).
In recognition that cancer is fundamentally a genetic
disease (Weber, 2002; Vogelstein and Kinzler, 2004), knowl-
edge of the critical mutations underlying tumor initiation
and progression, along with a growing array of targeted
therapeutics, offer tremendous potential in improving the
diagnosis and treatment of cancer (Demetri et al., 2002;
Kantarjian et al., 2002; Paez et al., 2004). Early cytogenetic
studies in CTCL suggested potential patterns in DNA copy-
number mutations (Mao et al., 2002, 2003) and, importantly,
some of these alterations, such as gain of 8q and loss of 6q
and 13q, are associated with shorter survival (Fischer et al.,
2004). Multiple levels of cellular dysregulation, restricted
sample size, low-resolution data, and limited clinical
information, however, have encumbered the discernment
of the primary biological pathways in this malignancy. With
accumulating genomic data and increased microarray
resolution, additional candidate regions have been identified
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(Vermeer et al., 2008; Caprini et al., 2009; Laharanne et al.,
2010), and now more recent advances in microarray
technologies, coupled with improved computational algo-
rithms, offer the unique opportunity to characterize the CTCL
genome to the subgene level and study various modes of
mutations.
Validation of genomic findings, however, is also limited
by the lack of a genomically annotated in vitro system.
Despite the challenges of ex vivo culture of CTCL cells in the
absence of other cell interactions, a limited number of
established CTCL cell lines do exist; yet, how representative
these cell lines are of freshly derived patient samples is
unclear. Established cell lines originally isolated from Se´zary
syndrome patients may require additional growth factors and
are numerous passages from the initial patient, yet with a
detailed knowledge of their genomes, our ability to perturb
and assess CTCL biology could be greatly enhanced.
Ultimately by characterizing the genomic landscape in
leukemic CTCL, at both the DNA and RNA level and in the
context of genetically characterized cell lines, we have begun
to pinpoint potential targets and offer a framework in which
to further study the mechanisms underlying transformation
and pathogenesis in this malignancy.
RESULTS
Copy-number analysis identifies regions containing putative
oncogenes and tumor suppressors
During malignant progression, acquired genetic alterations
that confer a survival advantage would be expected to be
selected for and altered at a higher rate. Therefore, identifying
statistical outliers should determine regions of the genome
with genes of potential biological significance. Our genomic
DNA-based analysis sought to determine these ‘‘driver’’
copy-number mutations using an algorithm termed GISTIC
(Genomic Identification of Significant Targets in Cancer;
Beroukhim et al., 2007), which has proven successful in
identifying both known and new oncogenes and tumor
suppressors in multiple other cancers (Beroukhim et al.,
2007, 2010; Weir et al., 2007; Lin et al., 2008). GISTIC takes
into account both the frequency of a DNA gain or loss
and the magnitude of this gain or loss at each probe.
By comparing this calculated score to the background null
hypothesis score, a significance value at each probe
throughout the genome is determined. Significantly altered
regions of the genome can then be further investigated for
candidate oncogenes and tumor suppressors.
The CTCL landscape for amplifications based on GISTIC
analysis of our samples is shown in Figure 1a, with
significance per probe plotted across the genome. We
identified 17 regions of amplifications in the CTCL genome
seen in red (Figure 1a and Supplementary Table S1a online)
and 40 regions of deletion in blue (Figure 1b and
Supplementary Table S1b online). The most significant
amplifications involved large regions of gain on 8q and
17q, in addition to many focal amplifications. Overall, there
were many more regions of deletion than amplification,
with the most significant deletions on 17p and 10. These
regions of chromosomal amplification and loss are shown in
Supplementary Table S1 online. We also identified focal
amplifications of 4q12 including KIT and 7p11.2 including
EGFR (Figure 1a, Supplementary Table S1a online). Although
these amplifications were only found in a subset of samples,
4 of 23 (17%) and 3 of 23 (13%), respectively, half of those
with 4q12 amplifications, and all of those with 7p11.2
amplifications, were noted to have nonresponsive or wor-
sened skin disease after 1 year of treatment (Table 1 and
Figure 3a). These amplifications could not be validated by
PCR because of insufficient patient sample; however, given
the potential clinical relevance and available targeted
therapeutics, further exploration in vitro and in larger cohorts
may be warranted. Moreover, VEGFA (vascular endothelial
growth factor receptor ) is another oncogene for which
targeted therapy is available, and is the closest well-validated
cancer gene to the focal amplification on 6p21.1 in 3 of 23
(13%) patients (Supplementary Table S1a online and Figure
3a). Thus, starting from the whole genome, the GISTIC
algorithm narrowed and prioritized a list of candidate
genes for further study.
Consensus analysis of the leukemic CTCL genome
The clinical heterogeneity and relative rarity of CTCL have
hindered the genomic characterization of CTCL. To address
some of these concerns, we performed a meta-analysis of
published data focusing on patients with Se´zary syndrome,
integrating regions of amplification and deletion from
108 samples comprising 7 studies (Supplementary Table S2
online), including our own, to create a consensus view of the
CTCL genome (Figure 2). In total, we determined 21 regions
of amplification and 42 regions of deletion. Notably, all of
our samples had significant copy-number alterations and
many patterns in the consensus analysis mirrored our GISTIC
analysis (Figure 1 and Supplementary Table S1 online), thus
corroborating our data set and analysis. A majority
of minimal common regions were narrowed and defined by
our study (38 of 63 regions), and there were no instances
where a region was found in all of the studies except ours.
Annotating these regions, we identified known oncogenes
and tumor suppressors in addition to candidates that, to our
knowledge, have not been previously reported. The most
significant gain was a broad region on 8q, including MYC.
This finding supports results from Vermeer et al. (2008) and
Laharanne et al. (2010) suggesting the primary role ofMYC in
oncogenesis. The second most significant region of gain
encompasses a large region on 17q that has yet to be fully
studied in CTCL. STAT3 (signal transducer and activator of
transcription 3) has previously been suggested as a candidate
of gain at this locus (Vermeer et al., 2008); however, in
our analysis, STAT3 is not at the peak, implying that there
may be other gene targets of the amplification and drivers of
oncogenesis on 17q. Although our analysis identified
genes involved in many cancers, potential CTCL-specific
oncogenes were also considered. A focal amplification of
10p13 including GATA3 (GATA binding protein 3), a
transcription factor that promotes T-helper 2 cytokine
skewing (Skapenko et al., 2004; Ho et al., 2009), was also
identified. The importance of GATA3 in CTCL was previously
www.jidonline.org 189
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proposed based on a supervised gene expression analysis (Kari
et al., 2003). Its amplification in malignant cells may thus
represent one mechanism of its activation and consequent
CTCL-mediated suppression of cell-mediated immunity via T-
helper 2 cytokine production. Deletions were most commonly
found on chromosome 17p with TP53 nearby, chromosome
10 including PTEN and FAS, 13q including RB1, and 9p21.3
including CDKN2A, reaffirming previous findings (Vermeer
et al., 2008; Caprini et al., 2009; Laharanne et al., 2010).
17q amplification candidate targets
Ultimately, one of the goals of cancer genomics is tying
patient genotype to clinical phenotype to better understand
pathogenesis and identify opportunities to therapeutically
intervene. After defining the most significant copy-number
alterations in CTCL, we used unsupervised pattern recogni-
tion algorithms to determine whether any clinical phenotypes
were linked to copy-number alterations (Figure 3a). Using
hierarchical clustering, we found 17q25.1 amplification to be
more common in patients who did not appear to improve and
had stable/worsened skin disease after 1 year of treatment
(Figure 3b, Fisher’s exact test, P-value 0.026), although this
was not significant when using a Bonferroni correction for
multiple hypotheses. Seeking to identify candidate targets of
amplification at this locus, we integrated gene expression
data with our copy-number analysis (Figure 3c). Comparing
samples with and without 17q25.1 gain, we identified genes
that were both amplified and differentially overexpressed.
This analysis was additionally performed in an independent
matched data set of CTCL samples with blood involvement
(Caprini et al., 2009). Two genes from our consensus analysis
(Figure 2) were identified: RPS6KB1 from the analysis of
the data set of Caprini et al. (2009), and GRB2 from our
data set. RPS6KB1 is involved in the phosphatidylinositol
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Figure 1. Significant DNA copy-number alterations in leukemic cutaneous T-cell lymphoma (CTCL). Statistically significant (a) amplifications and (b) deletions
pinpointed by GISTIC (Genomic Identification of Significant Targets in Cancer) aggregate analysis of 23 CTCL patient samples. Chromosomal location is
across the bottom with labeled cytobands corresponding to the center of the region and cancer-related genes from Beroukhim et al. (2010), or known
CTCL genes labeled above the region. *A gene adjacent to the peak region. Significance reported as false discovery rate–corrected q-value.
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3-kinase/mammalian target of rapamycin pathways and its
amplification and overexpression is believed to affect prog-
nosis in breast cancer (Heinonen et al., 2008). GRB2 is
involved in mitogen-activated protein kinase signaling and
therapeutic targets are already under development (Bocanegra
et al., 2010). Finally, overlapping genes in common included
PRKAR1A and USP32 (Figure 3c). It is noteworthy that
PRKAR1A regulates cAMP levels and has been found to
induce 3- to 4-fold increased expression of IL-2 when it is
overexpressed (Elliott et al., 2004). Moreover, we found that
IL-2 receptor-b expression, the receptor subunit that binds
IL-2 and has been specifically linked to proto-oncogene
induction (Manoukian et al., 2009), was concordantly highest
in patients with PRKAR1A amplifications in comparison
with those without amplifications. Thus, we consider that
PRKAR1A amplification may represent one mechanism of
IL-2 pathway activation, potentially enhancing malignant
T-cell proliferation through upregulation of JAK/STAT, phos-
phatidylinositol 3-kinase/AKT, and mitogen-activated protein
kinase pathways (Elliott et al., 2004; Manoukian et al., 2009).
Genomic comparison of leukemic CTCL cell lines and
leukemic CTCL patient samples
Given the challenges of isolating malignant cells in CTCL,
and the difficulty in culturing cells from patients, many
investigators have used established CTCL lines for in vitro
studies. A major concern of cell line models is the potential
dissimilarity between cell lines, which have undergone
multiple passages and sometimes require additional growth
factors, and primary patient samples. To address this
question, we generated DNA copy-number and mRNA
expression data for five established cell lines derived from
the peripheral blood of Se´zary syndrome patients: HH,
HUT78, PNO, SeAx, and Sez4 (Supplementary Table S3
online). In Figure 4, we display all significant copy-number
alterations in these cell lines defined by GISTIC analysis
(details of regions in Supplementary Table S4 online) and
compare them with genetic alterations from our 23 patient
samples and meta-analysis. Overall, there were many
similarities, and the core features of leukemic CTCL, gain
of 8q and 17q, and loss of chromosome 10 and 17p were
maintained. Among the most significant genetic alterations in
common between primary leukemic CTCL samples and the
representative cell lines were the following: deletion of
9p21.3 wherein lies CDKN2A (cyclin-dependent kinase
inhibitor 2A), and amplification of 8q24.21 wherein lies
MYC. Other recurrent regions in common with meta-analysis
results included amplification of 17q21.31 and deletion of
10q23.31, 10q25.1, and 13q14.2. There were, nevertheless,
also some notable differences. Alterations seen in HH and
HUT78 cell lines, which were not significantly observed in
primary samples, were gain of a region on 4q24–q26 and loss
of 4q35.1 and 6q21 (Figure 4, Supplementary Tables S1 and
S4 online). In addition, on a relative scale, chromosome
17p loss and 17q gain were present, but less pronounced, in
the cell lines. Thus, although there are several additional
alterations in some of the cell lines, our studies revealed that
these established cell lines do demonstrate core genomic
features of primary leukemic CTCL patients and identified
those specific differences.
DISCUSSION
CTCL continues to offer unique opportunities to study T-cell
biology and cancer. Advances in genomic technology
along with improved modeling and an increasing number
of genomic studies are steadily expanding our knowledge of
the mutations underlying both malignant T-cell transforma-
tion and the immunogenic aspects of CTCL. Our high-
resolution analysis and meta-analysis of patients with
leukemic disease helps discern some of the common DNA
copy-number alterations characteristic of CTCL, and we will
continue to learn more as we study the mutations of patients
with variable skin (e.g., patch, plaque, tumor, erythrodermic)
and blood involvement, and those ranging from the earliest to
the most advanced stages of disease.
Despite their promise, genomic studies in CTCL must
navigate many challenges. Foremost are limitations presented
by sample size and data quality, which are affected by both
the purity and yield of malignant cell isolation. These hurdles,
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Figure 2. Consensus analysis of the leukemic cutaneous T-cell lymphoma
(CTCL) genome. Analyzing seven CTCL genomic studies (Mao et al., 2002,
2003; Fischer et al., 2004; Vermeer et al., 2008; Caprini et al., 2009;
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region. Cancer-related genes from Beroukhim et al. (2010) are shown in the
final column.
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largely due to the low incidence and heterogeneity of disease
and technical options available, continue to restrain the
potential contribution of genomics to our understanding of
CTCL biology. Our desire to understand key genes in
pathogenesis led us to incorporate a spectrum of CTCL
patients with variable blood involvement, predominantly
including those with earlier stages of disease. Focusing on
patients with early stages of disease may have allowed us to
concentrate on early genetic events and enriches for ‘‘driver’’
mutations, as opposed to ‘‘passenger’’ events that occur as a
result of genomic instability.
Despite this potential benefit, characterizing early leuke-
mic disease makes concerns about malignant cell isolation
particularly critical to consider. Ultimately, we utilized loss
of the immunophenotypic markers CD7 and/or CD27 to
enrich for the malignant cells in the population we isolated.
The loss of CD7 expression has often been correlated with
expansion of clonal T cells in CTCL, and the dominant clone
in CTCL patients has been observed to have a CD4þCD7
phenotype (Rappl et al., 2001). Although this phenotype can
also be found in reactive T-cell populations, it may never-
theless be the most common major T-cell antigen lost, with
46 to 76% of leukemic CTCL patients showing decreased
CD7 expression (Klemke et al., 2008). Similarly, loss of CD26
has also been used as a marker for leukemic CTCL, being
found in clonal T-cell populations and estimated to occur in
59.3% of Se´zary syndrome patients (Klemke et al., 2008).
Notably, CD4þCD26 populations have also been found to
significantly correlate with the percentage of Se´zary cells
within the lymphoid population and, in particular, have been
found to be expanded in patients with CD4/CD8 ratios o10
(Bernengo et al., 2001). Neither of these markers are ideal, as
there exist normal cells expressing these immunophenotypes;
however, in the setting where a CD7 or CD26 population
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Figure 3. 17q25.1 amplification candidate targets. (a) Unsupervised analysis of significant copy-number (CN) mutations in cutaneous T-cell lymphoma (CTCL)
as defined by GISTIC (Genomic Identification of Significant Targets in Cancer) analysis was performed with hierarchical clustering. Each patient’s skin
disease severity after 1 year of treatment is annotated next to the sample number. (b) Fisher’s exact test showed 17q25.1 amplification to be more common
in patients with stable/worsened skin disease after 1 year of treatment; however, this was not significant after Bonferroni multiple-hypothesis correction.
(c) Using Comparative Marker Selection, differential expression analysis of samples with 17q25.1 amplification versus no amplification reveals candidate
targets that are amplified and overexpressed in the data set of Caprini et al. (2009; shown in red), our data set (shown in blue), and the overlap (shown in purple).
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was expanded outside of normal ranges, we effectively used
these markers to more specifically select and enrich for the
dominant malignant clone.
The potential ramifications of reduced malignant cell
purity affect all leukemic CTCL genomic studies and the
resulting data must be viewed in light of isolation methodol-
ogy limitations and the patient population. Gene expression
values can be biased as a direct result of cell population
contaminants. Moreover, gene expression was also likely
affected by the different therapies each patient received;
however, the impact of these treatments could not be
identified in global clustering. DNA copy-number changes
are theoretically more robust, but there can be attenuation
of absolute signal from normal cell admixture. Notably, all of
our samples had copy-number alterations, even those
isolations from patients with relatively small changes in flow
cytometric parameters. Nevertheless, had they not (e.g., due
to isolation of the incorrect population of cells or inclusion of
a patient with undetectable malignancy), our copy-number
algorithm was designed to remove samples without any
significant copy-number alterations from inclusion in further
analysis. Additional concerns about the data purity and
quality are also partially alleviated through the meta-analysis,
which enabled not only increased sample size but also
allowed us to place our study in the context of other
published data.
Our consensus analysis included six other genomic studies
that focused on Se´zary syndrome patients; i.e., those with
more advanced leukemic disease. The results of this analysis
and the similarities of alterations on a genome-wide level
between our data and these other data sets corroborate our
own analysis. Indeed, it appears that our samples captured a
large proportion of the genomic diversity in leukemic CTCL
with some patterns characteristic of malignancy observed
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even in our patients with early levels of blood involvement.
These loci of recurrent gains and losses, observed in both
Se´zary syndrome patients and our patients, who are skewed
toward earlier stages of disease, thus likely contain genes
perturbed at an early stage that have a role in pathogenesis.
In addition, including data and analysis from 108 patients
enabled us to determine recurrent commonalities in DNA
copy-number alterations resulting in one of the more
comprehensive descriptions of the leukemic CTCL genome.
At the same time, we recognize that this view reflects an
evolving picture that we hope will be built upon and refined
by future studies to further our understanding of the genomic
landscape in CTCL.
Although the genomic landscapes are similar from a global
view between our patients with early leukemic disease and
other studies of patients with more advanced disease, we also
make direct comparisons at individual loci. By generating our
own high-resolution data set and then using an algorithm
that identified driver genetic mutations, we narrowed and
verified significant regions of gain and loss in leukemic CTCL.
Our analysis confirmed findings from previous studies such as
the significance of 8q amplification including MYC, chromo-
some 10 loss including PTEN and FAS, 9p21.3 deletion
including CDKN2A, 13q deletion including RB1, and 17p
loss including TP53. In addition, we began to narrow regions
with 38 of the 63 regions in the meta-analysis refined by
our analysis. In particular, we focused on 17q and, through
integration of gene expression data, identified genes of
interest that, to our knowledge, have not been previously
reported.
We also notably discovered copy-number amplifications
within or adjacent to KIT, EGFR, and VEGFA. Cancer
is increasingly classified and additionally defined by key
mutations. The discovery of these amplifications obligates
further study as to whether a subset of CTCL patients may
benefit from targeted therapies, in addition to any potential
roles these genes and their products may have in cutaneous
biology. Clinical data offer the possibility of correlating
genotype to clinical phenotype to help delineate important
biology. Unfortunately, our analyses were limited by our
sample number and no significant correlations could
be made.
In our cluster analysis of significant copy-number altera-
tions, we found 17q25.1 amplification to be more common
in patients with stable/progressive skin disease 1 year after
treatment than those who did not improve; however, the
association was not significant after multiple hypothesis
correction. Additional confounders include the multiple
treatment options that these patients received as seen
in Table 1. Nevertheless, 17q25.1 was the second most
significant region of amplification, making it an extreme
statistical outlier. This, together with the fact that a total of
B44% samples from our consensus analysis included a
17q25 gain, suggests that there are genes at or near this locus
driving oncogenesis. Using orthogonal genomic expression
data focusing on samples that are amplified and differentially
over-expressed in two data sets, PRKAR1A was nominated
from our list of candidates. In our cell line data, PRKAR1A
had among the highest mean expression of all genes on
chromosome 17 (ranked 11th of 1235 genes; data not shown)
and indeed the entire genome (98.7th percentile of expres-
sion; data not shown). Given the importance of the IL-2
pathway in CTCL and the availability of denileukin difitox,
PRKAR1A represents an interesting target meriting in vitro
validation and further study. It is important to note, how-
ever, that broad gain of 17q suggests multiple oncogenic
targets and therefore PRKAR1A is likely not the sole focus
of amplification. Indeed, GRB2 and RPS6KB1 represent
other candidates in addition to STAT3. Thus, although the
potential role of PRKAR1A in activating the IL-2 pathway is
conceivable, more importantly, our analysis provides a
framework with which to prioritize future functional work.
Hopefully, future studies with full clinical data and larger
numbers will enable informative clinical correlations.
Looking toward the potential development of biomarkers
and targeted therapeutics, functional validation of genomic
hypotheses will require robust, genetically characterized
in vitro and in vivo models. We hope to have aided this
effort through our profiling of five established cell lines from
Se´zary syndrome patients. Although these lines contain some
commonalities with primary leukemic patients, there are
also additional genetic alterations not observed in our meta-
analysis of 108 patient samples. Whether these genetic
alterations represent a small proportion of true CTCL biology
or whether they reflect new mutations from selection under
culture is unclear. Thus, these cell lines should not be used
blindly. Individual experiments will hopefully benefit from
our genomic annotation, and together they may serve as an
initial framework in which to embark upon functional
validation of genomic hypotheses and potential pharmaco-
genomic endeavors. Finally, as more studies are published
and sample size grows, the ability to perform meta-analyses
and correlate genotypes to clinical phenotypes will reveal
additional avenues and insights into the interface of cancer
biology and immunology in this malignancy.
MATERIALS AND METHODS
Patient selection and clinical data collection
Genomic data (DNA data from 23 patients, mRNA data from
12 patients, and 11 patients with both) was generated from the
peripheral blood of 24 patients at the Yale Cutaneous Lymphoma
Center clinic over a 3-month period in 2008. All patients were
treated with extracorporeal photopheresis on a monthly basis.
Although the primary focus of study was on patients with early
blood involvement, several patients with advanced disease were also
included (exclusion and inclusion criteria and rationale for patient
selection are detailed in Supplementary Information online). Some
patients additionally received therapies such as bexarotene, metho-
trexate, IFN-a, or vorinostat (Table 1). Briefly, criteria for study
inclusion included at least 10% body surface involvement (T2) skin
disease, as well as demonstration of peripheral blood involvement
by one or more of the following: (1) positive PCR for TCR-b/g
in blood, or (2) expansion of CD4þCD7, CD4þCD26, or
CD45RO populations outside of normal ranges, or (3) Va or b family
expansion outside of normal ranges. The majority of patients showed
limited blood involvement (e.g., CD4/CD8 ratios o10), although
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patients 5, 10, and 14 fulfilled a diagnosis of Se´zary syndrome.
Written informed consent was obtained in accordance with the
Declaration of Helsinki Principles and approval was obtained from
the Yale School of Medicine Human Investigation Committee.
Clinical information was gathered at the time of sample collection
and 1 year later (Table 1 and Supplementary Table S5 online).
Isolation of enriched malignant cell populations
In the final cycle of leukapheresis before 8-methoxypsoralen
exposure, lymphocyte-enriched blood was drawn from each patient,
and whole blood was drawn from age- and sex-matched controls.
All samples were processed similarly. Blood was layered
on Isolymph and processed as described by the manufacturer
(CTL Scientific Supply, Deer Park, NY), and detailed in Supplemen-
tary Information online. Using flow cytometric parameters,
expanded populations representing X20% of the peripheral blood
were identified and sorted for CD4þCD7, CD4þCD26, or
CD4þCD7CD26 populations. Otherwise, the CD4þ popula-
tion was isolated. Negative selection followed by positive selection
was performed using the Magnetic-bead Antibody Cell Sorting LS
column and magnet following the manufacturer’s instruction
(Miltenyi Biotech, Auburn, CA), and detailed in the Supplementary
Information online. FACS was performed after isolation to confirm
purity X70% (mean 96%, median 99% CD4þ ).
Cell lines and culture conditions
HUT78, HH, SeAx, Sez4, and PNO were kindly provided by
collaborators and were originally derived from the peripheral blood
of Se´zary syndrome patients (please see Supplementary Table S3
online for details). Each was maintained in culture at 37 1C, 5%
CO2, in specific media described in Supplementary Table S3 online.
Genomic data generation
From the freshly isolated cells and cell lines, RNA was extracted
using Qiagen RNeasy kit and stored in RNAlater (Qiagen, Valencia,
CA), and DNA was extracted using Puregene (Gentra, Valencia, CA)
and stored in TE buffer. After standard quality control measurements
and quantification, 500 ng of genomic DNA was input for human
SNP 6.0 arrays and 300ng of total RNA was input for human Gene
1.0 ST arrays (Affymetrix, Santa Clara, CA) at the Keck Microarray
Core facility, according to the manufacturer’s specifications. Details
about data access, assays, and quality controls are in Supplementary
Information online.
Copy-number analysis
Genomic data were processed using algorithms written in MATLAB
and packages in GenePattern (Reich et al., 2006). Affymetrix.
CEL files were converted to .SNP files by an adaption of SNP File
Creator for SNP 6.0. GISTIC preprocessing and normalization were
done as described previously (Beroukhim et al., 2007; Lin et al.,
2008). GISTIC parameters are further detailed in Supplementary
Information online.
Consensus analysis
Studies used in the consensus analysis focused on CTCL patients
with blood involvement, specifically Se´zary syndrome (Supplemen-
tary Table S2 online). Lower-resolution studies with o10 patients
included all available data. Higher-resolution studies with 410
patients only included regions identified by each study’s respective
authors. Common regions were defined by at least two studies and
minimal common regions were defined by at least one study.
Cancer-related genes were annotated from genes identified in
Beroukhim et al., 2010.
Cluster analysis
Significant regions of amplifications and deletions defined by GISTIC
were analyzed using hierarchical clustering (Pearson’s correlation,
complete linkage; Figure 3a, detailed in Supplementary Information
online). 17q25.1 was identified through visual analysis of clusters
and with Fisher’s exact test (Figure 3b).
Gene expression integration with DNA copy number
Gene expression was integrated with copy number through
Comparative Marker Selection (parameters in Supplementary
Information online). Samples with an amplification in the region
were compared with those without an amplification to identify
differentially expressed genes (Figure 3c). GSE17601 (Caprini et al.,
2009) was downloaded with GEOImporter and annotated using
GeneCruiser.
Cell line analysis
Cell line SNP array data were processed as described above in
copy-number analysis section. A heatmap of 28 samples (5 cell lines
and 23 patient samples) was generated from the all_lesions file as
part of standard GISTIC output. Cancer-related genes were annotated
from genes identified in Beroukhim et al. (2010).
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